Institute of Digestive Diseases, Longhua Hospital, China-Canada Center of Research for Digestive Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
Department of Biochemistry, University of Ottawa, Ottawa K1H 8M5, ON, Canada.
World J Gastroenterol. 2024 Aug 28;30(32):3726-3729. doi: 10.3748/wjg.v30.i32.3726.
The emergence of immunotherapy, particularly immune checkpoint inhibitors (ICIs), represents a groundbreaking approach to treating gastric cancer (GC). However, the prognosis of GC patients receiving ICI treatment is influenced by various factors. This manuscript identified sarcopenia and myosteatosis as inde-pendent prognostic factors impacting the outcomes of GC patients treated with ICIs. Additionally, this study introduced a visual predictive model to estimate the prognosis of GC patients. If confirmed by further studies, this observation could provide valuable insights to propel the advancement of personalized clinical medicine and the integration of precision medicine practices.
免疫疗法的出现，特别是免疫检查点抑制剂（ICI）的出现，代表了治疗胃癌（GC）的一种突破性方法。然而，接受 ICI 治疗的 GC 患者的预后受到多种因素的影响。本研究确定了肌肉减少症和肌内脂肪变性是影响接受 ICI 治疗的 GC 患者结局的独立预后因素。此外，本研究引入了一个可视化预测模型来估计 GC 患者的预后。如果进一步的研究得到证实，这一观察结果可能为推动个性化临床医学的发展和精准医学实践的整合提供有价值的见解。
